MPTP: insights into parkinsonian neurodegeneration.
暂无分享,去创建一个
[1] G. Cohen,et al. Monoamine oxidase and oxidative stress at dopaminergic synapses. , 1990, Journal of neural transmission. Supplementum.
[2] M. Beal,et al. Novel Free Radical Spin Traps Protect against Malonate and MPTP Neurotoxicity , 1999, Experimental Neurology.
[3] Wade K. Smith,et al. Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization , 1989, Annals of neurology.
[4] R. S. Burns,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.
[5] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Snyder,et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Jarvis,et al. Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) , 1985, Neuropharmacology.
[8] S. Mandel,et al. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.
[9] Y. Yamamura,et al. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms , 1973, Neurology.
[10] M. Schwarzschild,et al. Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[11] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[12] Ole A. Andreassen,et al. Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP , 2001, Experimental Neurology.
[13] R. Duvoisin. Is Parkinson’s Disease Acquired or Inherited? , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[14] S. Korsmeyer,et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[15] B. Westerink,et al. Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+. , 1986, European journal of pharmacology.
[16] Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP) , 1989, Acta neurologica Scandinavica. Supplementum.
[17] Philippe Hantraye,et al. MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.
[18] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[19] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[20] S. Snyder,et al. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.
[21] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Dichgans,et al. Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.
[23] J W Langston,et al. MPTP: current concepts and controversies. , 1986, Clinical neuropharmacology.
[24] P. Riederer,et al. Is there neuroprotection in Parkinson syndrome? , 2000, Journal of Neurology.
[25] R. Ramsay,et al. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. , 1987, Archives of biochemistry and biophysics.
[26] C. W. Olanow,et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.
[27] P. Mcgeer,et al. Relationship of Complement-Activated Oligodendrocytes to Reactive Microglia and Neuronal Pathology in Neurodegenerative Disease , 1991 .
[28] A. Schapira. Mitochondrial complex I deficiency in Parkinson's disease. , 1989, Advances in neurology.
[29] Virginia M. Y. Lee,et al. Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.
[30] J. Parkinson. An Essay on the Shaking Palsy , 2002 .
[31] M. Beal,et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Minoshima,et al. Familial Parkinson's disease. Alpha-synuclein and parkin. , 2001, Advances in neurology.
[33] M. Vila,et al. α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.
[34] J. Keller,et al. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins , 2001, Journal of neurochemistry.
[35] Calne,et al. Parkinson's disease is not one disease. , 2000, Parkinsonism & related disorders.
[36] S. Paul,et al. The N‐Methyl‐D‐Aspartate Antagonist MK‐801 Fails to Protect Dopaminergic Neurons from 1‐Methyl‐4‐ Phenylpyridinium Toxicity In Vitro , 1993, Journal of neurochemistry.
[37] S. Parvez,et al. Cell death induced by MPTP, a substrate for monoamine oxidase B. , 2000, Toxicology.
[38] R. Reiter,et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. , 1996, Life sciences.
[39] K. McNaught,et al. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release , 2000, Neuroscience Letters.
[40] A Hartley,et al. Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.
[41] O Rascol,et al. Dopamine agonists. Their role in the management of Parkinson's disease. , 2001, Advances in neurology.
[42] S. Korsmeyer,et al. Enhanced Oxidative Stress and Altered Antioxidants in Brains of Bcl‐2‐Deficient Mice , 1998, Journal of neurochemistry.
[43] C. Saper,et al. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease , 1985, Annals of neurology.
[44] Junying Yuan,et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.
[45] M. Smeyne,et al. Strain‐dependent susceptibility to MPTP and MPP+‐induced Parkinsonism is determined by glia , 2001, Glia.
[46] C. Kawas,et al. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. , 1997, The Journal of clinical investigation.
[47] S. Korsmeyer,et al. BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.
[48] R. Krüger,et al. Parkinson's disease--a multifactorial neurodegenerative disorder. , 1999, Journal of neural transmission. Supplementum.
[49] J. Cano,et al. Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.
[50] Y. Kitamura,et al. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice , 1994, Journal of Neuroimmunology.
[51] J. Adams,et al. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain? , 1991, Biochemical pharmacology.
[52] J. Bennett,et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[53] J B Schulz,et al. Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice , 2001, Journal of neurochemistry.
[54] A. Członkowska,et al. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Immunopharmacology.
[55] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[56] J. Schulz,et al. Introduction: Targeted Modulation of Neuronal Apoptosis: A Double‐Edged Sword? , 2000, Brain pathology.
[57] R. Ramsay,et al. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.
[58] L. Grégoire,et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys , 1999, Neurology.
[59] S. Khuder,et al. Environmental risk factors and Parkinson's disease: a metaanalysis. , 2001, Environmental research.
[60] Juliek . Andersen,et al. The Role of Iron in Parkinson Disease and 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity , 1999, IUBMB life.
[61] P. Sonsalla,et al. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. , 1991, The Journal of pharmacology and experimental therapeutics.
[62] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[63] D. German,et al. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. , 2000, The Journal of pharmacology and experimental therapeutics.
[64] A. Levey,et al. Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice , 1998, Journal of neurochemistry.
[65] I. Vermes,et al. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism , 1999, Neuroscience Letters.
[66] R. Heikkila. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. , 1985, European journal of pharmacology.
[67] B. Ferger,et al. Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.
[68] M. Mattson,et al. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults , 1994, Brain Research.
[69] G. Tucker,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. , 1996, The Journal of pharmacology and experimental therapeutics.
[70] E. Hirsch,et al. Neuronal vulnerability in Parkinson's disease. , 1997, Journal of neural transmission. Supplementum.
[71] L. Carr,et al. Inhibition of uptake of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components. , 1992, European journal of pharmacology.
[72] R. Krüger,et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.
[73] R. Duvoisin,et al. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.
[74] C. Tanner,et al. Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease , 1998, Neurology.
[75] J. Cummings. Understanding Parkinson disease. , 1999, JAMA.
[76] S. Mandel,et al. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. , 2001 .
[77] K. Tipton,et al. Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.
[78] E. Hirsch,et al. Parkinson's disease. The apoptosis hypothesis revisited. , 2001, Advances in neurology.
[79] M. Goedert,et al. Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.
[80] Y. Mizuno,et al. Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains , 1987, Neuroscience Letters.
[81] K. Castagnoli,et al. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. , 2001, Chemical research in toxicology.
[82] R A Koeppe,et al. Imaging the vesicular monoamine transporter. , 2001, Advances in neurology.
[83] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[84] S. Fahn,et al. Neurotoxicity of levodopa on catecholamine‐rich neurons , 1992, Movement disorders : official journal of the Movement Disorder Society.
[85] Genetic polymorphisms in Parkinson's disease. , 1998, Neurotoxicology.
[86] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[87] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[88] I. Shoulson. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. , 1998, Annals of neurology.
[89] R. Clavier,et al. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse , 1985, Neuroscience Letters.
[90] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[91] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[92] Christina A. Wilson,et al. Tau and α-Synuclein in Neurodegenerative Diseases , 2001 .
[93] S. Ho,et al. Further studies in xenobiotic metabolism and Parkinson's disease. , 2001, Advances in neurology.
[94] D. German,et al. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter , 1998, Neuroscience.
[95] R. Duvoisin,et al. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice. , 1986, European journal of pharmacology.
[96] Z. Wszolek,et al. Reduced expression of the G209A α‐synuclein allele in familial parkinsonism , 1999 .
[97] R. Ramsay,et al. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.
[98] A. Seidler,et al. Smoking and Parkinson's disease: a case-control study in Germany. , 1997, International journal of epidemiology.
[99] J W Langston,et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.
[100] C D Marsden,et al. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. , 1998, Biochemical pharmacology.
[101] A. Zuddas,et al. In Brown Norway Rats, MPP+ Is Accumulated in the Nigrostriatal Dopaminergic Terminals but It Is Not Neurotoxic: A Model of Natural Resistance to MPTP Toxicity , 1994, Experimental Neurology.
[102] M. Beal,et al. S-Methylthiocitrulline, a Neuronal Nitric Oxide Synthase Inhibitor, Protects against Malonate and MPTP Neurotoxicity , 1997, Experimental Neurology.
[103] E. Domino,et al. In vivo imaging of monoaminergic nerve terminals in normal and MPTP‐lesioned primate brain using positron emission tomography (PET) and [11C]tetrabenazine , 1993, Synapse.
[104] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[105] B. Bogerts,et al. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. , 1983, Biological psychiatry.
[106] J. Cooper,et al. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins , 1998, Brain Research.
[107] T. Di Paolo,et al. Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice , 2001, Synapse.
[108] B. Cooper,et al. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. , 1994, Life sciences.
[109] Y. Agid,et al. Peptides and Parkinson's disease , 1985, Trends in Neurosciences.
[110] C. Marsden,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.
[111] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[112] E. Hirsch,et al. FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.
[113] Langston Jw,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .
[114] D. Dluzen,et al. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system , 2001, Neuroscience.
[115] C. Carter,et al. Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.
[116] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[117] P. Yates,et al. PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE , 1983, Neuropathology and applied neurobiology.
[118] F. Vaglini,et al. Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors , 1998, Journal of neurochemistry.
[119] M. Zimmermann,et al. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice , 1996, Neuroscience Letters.
[120] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[121] O. H. Viveros,et al. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[122] Erwan Bezard,et al. Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter , 1999, Experimental Neurology.
[123] D. Murphy,et al. In Vivo Generation of Hydroxyl Radicals and MPTP‐Induced Dopaminergic Toxicity in the Basal Ganglia , 1994, Annals of the New York Academy of Sciences.
[124] M. Youdim,et al. Free radical scavengers: chemical concepts and clinical relevance. , 1999, Journal of neural transmission. Supplementum.
[125] P. Sonsalla,et al. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. , 2000, The Journal of pharmacology and experimental therapeutics.
[126] R. Edwards,et al. Differential expression of two vesicular monoamine transporters , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[127] Annette M. Schmid,et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.
[128] T. Chase,et al. Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.
[129] P. Mcgeer,et al. Inflammation in Parkinson's disease. , 2001, Advances in neurology.
[130] E. Melamed,et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[131] V. Uversky,et al. The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.
[132] W. Nicklas,et al. Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐Phenylpyridinium , 1986, Journal of neurochemistry.
[133] M. Ebadi,et al. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 2001, Brain Research.
[134] G. Nisticó,et al. Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. , 1998, Pharmacology & toxicology.
[135] C. Ríos,et al. Participation of manganese-superoxide dismutase in the neuroprotection exerted by copper sulfate against 1-methyl 4-phenylpyridinium neurotoxicity , 2001, Brain Research Bulletin.
[136] S. Snyder,et al. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. , 1986, Neurology.
[137] A. Imperato,et al. The Antioxidant Ebselen Prevents Neurotoxicity and Clinical Symptoms in a Primate Model of Parkinson's Disease , 2000, Experimental Neurology.
[138] K. Jellinger,et al. Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.
[139] G. Campanella,et al. Ecogenetics of Parkinson's Disease: Prevalence and Environmental Aspects in Rural Areas , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[140] A. Novelli,et al. Neurotoxicity at the N‐Methyl‐D‐Aspartate Receptor in Energy‐Compromised Neurons An Hypothesis for Cell Death in Aging and Disease , 1989, Annals of the New York Academy of Sciences.
[141] T. Gasser. Molecular genetics of Parkinson's disease. , 2001, Advances in neurology.
[142] D. Mash,et al. Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease , 1999, Experimental Neurology.
[143] A. Lockwood. Pesticides and parkinsonism: is there an etiological link? , 2000, Current opinion in neurology.
[144] W. Willett,et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.
[145] H. L. Wiener,et al. (-)-2-Oxo-4-thiazolidine carboxylic acid attenuates 1-methyl-4-phenyl-1,1,2,3,6-tetrahydropyridine induced neurotoxicity , 1988 .
[146] J W Langston,et al. Parkinson disease in twins: an etiologic study. , 1999, JAMA.
[147] R. Duvoisin,et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.
[148] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[149] J. Langston,et al. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. , 1993, Advances in neurology.
[150] David Blum,et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.
[151] O. Andreassen,et al. Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.
[152] C. Tanner,et al. Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.
[153] M. Goedert,et al. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. , 1984, Biochemical pharmacology.
[154] W. Spooren,et al. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1998, Neuroscience.
[155] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[156] M. Farrer,et al. Low frequency of α‐synuclein mutations in familial Parkinson's disease , 1998, Annals of neurology.
[157] K. S. Yoon,et al. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats , 1998, Neuroscience Letters.
[158] R. Ramsay,et al. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.
[159] M. Hocquaux,et al. N,N'-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an "oxidative stress activatable" iron chelator in vitro. , 1995, Free radical research.
[160] S. Gilman,et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.
[161] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[162] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[163] V. Yong,et al. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment , 1986, Neuroscience Letters.
[164] S. Snyder,et al. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity , 1987, Nature.
[165] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[166] R. Ramsay,et al. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.
[167] E. Hirsch,et al. Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis , 2001, The Journal of Neuroscience.
[168] J. Parks,et al. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. , 1999, Biochimica et biophysica acta.
[169] M. Mattson,et al. Calcium and reactive oxygen species mediate staurosporine‐induced mitochondrial dysfunction and apoptosis in PC12 cells , 1998, Journal of neuroscience research.
[170] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[171] M. Mattson,et al. Participation of prostate apoptosis response‐4 in degeneration of dopaminergic neurons in models of Parkinson's disease , 1999, Annals of neurology.
[172] S. Przedborski,et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[173] W. Oertel,et al. The Protective Effects of PBN Against MPTP Toxicity Are Independent of Hydroxyl Radical Trapping , 2000, Pharmacology Biochemistry and Behavior.